 |
|
Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
May 28, 2009ROCHESTER, Minn. - Researchers have discovered a novel molecular path that predisposes patients to develop primary biliary cirrhosis, a disease that mainly affects women and slowly destroys their livers. Primary biliary cirrhosis has no known cause.
The finding, significant because it is a first step toward developing a targeted treatment and a cure, will be published in the June 11, 2009, issue of the New England Journal of Medicine.
"Now that we better understand the molecular basis of primary biliary cirrhosis, we can look for ways to specifically fix those elements," says Konstantinos Lazaridis, M.D., a Mayo Clinic hepatologist and a senior researcher in the study.
Currently, treatments for primary biliary cirrhosis can slow progression of the disease, which affects 1 in 2,500 Americans, 90 percent of them women. However, about half of patients do not respond to medical therapy. For some patients, a liver transplant cures the condition. But not all patients qualify for a transplant, and some transplant recipients experience a recurrence within five to 10 years.
The study was conducted at the University of Toronto using blood samples of patients collected at several medical centers in Canada and at Mayo Clinic's campus in Rochester, Minn., through its Primary Biliary Cirrhosis Genetic Epidemiology Research Resource. This resource comprises the biospecimens of hundreds of primary biliary cirrhosis patients and individuals who do not have the disease (controls) --matched for age, sex, race and state of residence. Mayo Clinic and the University of Toronto are among the largest treatment centers in North America for primary biliary cirrhosis.
The University of Texas MD Anderson Cancer Center in Houston provided historical controls and conducted the statistical analysis of the study.
The genetic link to primary biliary cirrhosis has been well-established by previous studies. "Indeed, mothers, sisters and daughters in the same family have a significantly higher tendency to develop the disease compared with the general population," says Dr. Lazaridis.
To learn more about the cause of the illness, researchers designed a three-phase study to identify genetic markers associated with the disease. In phase one, researchers conducted a genome-wide association analysis, comparing the genotypes of 536 patients with primary biliary cirrhosis to those of 1,536 people who did not have the disease. Researchers looked at more than 300,000 single-nucleotide polymorphisms (SNPs), the most common genetic variations, among the approximately 11 million known to be present in the human genome.
"There were significant differences between the patients with primary biliary cirrhosis and the control group," says Dr. Lazaridis. As a result, researchers narrowed their focus to 16 SNPs significantly linked to primary biliary cirrhosis.
In phases two and three, researchers conducted "replication" and "fine-mapping" studies to confirm the initial results and to further detail the genetic variations most closely linked to primary biliary cirrhosis.
Researchers discovered that variants of two genes, interleukin 12A (IL12A) and interleukin 12RB2 (IL12RB2), were strongly associated with primary biliary cirrhosis. These two genes constitute a pathway of the immune system. Potential therapeutic manipulation of this pathway provides new possibilities for more effective treatments of these patients, says Dr. Lazaridis.
Researchers also confirmed that the human leukocyte antigen (HLA) region of the genome is linked to primary biliary cirrhosis, an association which had been identified in previous research. "Although both the HLA region and the IL12 pathway are equally involved with susceptibility to primary biliary cirrhosis, HLA is very complicated to dissect genetically, with multiple pathways," says Dr. Lazaridis. "It will be difficult to modulate with the intention to treat, while IL12 is a single pathway and thus more amenable to treatment."
The reliability of the newly discovered association is very strong; statistically, there's about a one in 10 trillion chance that the pathway isn't linked to primary biliary cirrhosis, Dr. Lazaridis noted.
"That strong association is remarkable, given that the researchers started by looking at 300,000 genetic markers across approximately three billion base pairs that comprise our entire genetic material," he says. "Needle in a haystack doesn't begin to convey the challenge of this search."
Dr. Lazaridis describes this finding as the "end of the beginning" in learning more about the predisposing genetic factors to primary biliary cirrhosis. The newly discovered IL12 pathway does not account for all instances of primary biliary cirrhosis. There is more work to be done on additional genetic links, and exactly how IL12A and IL12RB2 contribute to primary biliary cirrhosis remains unknown. But researchers now have, for the first time, the knowledge to begin to develop targeted treatments and better predict outcomes for some patients with primary biliary cirrhosis.
Mayo Clinic
Currently, treatments for primary biliary cirrhosis can slow progression of the disease, which affects 1 in 2,500 Americans, 90 percent of them women. However, about half of patients do not respond to medical therapy. For some patients, a liver transplant cures the condition. But not all patients qualify for a transplant, and some transplant recipients experience a recurrence within five to 10 years.
The study was conducted at the University of Toronto using blood samples of patients collected at several medical centers in Canada and at Mayo Clinic's campus in Rochester, Minn., through its Primary Biliary Cirrhosis Genetic Epidemiology Research Resource. This resource comprises the biospecimens of hundreds of primary biliary cirrhosis patients and individuals who do not have the disease (controls) --matched for age, sex, race and state of residence. Mayo Clinic and the University of Toronto are among the largest treatment centers in North America for primary biliary cirrhosis.
The University of Texas MD Anderson Cancer Center in Houston provided historical controls and conducted the statistical analysis of the study.
The genetic link to primary biliary cirrhosis has been well-established by previous studies. "Indeed, mothers, sisters and daughters in the same family have a significantly higher tendency to develop the disease compared with the general population," says Dr. Lazaridis.
To learn more about the cause of the illness, researchers designed a three-phase study to identify genetic markers associated with the disease. In phase one, researchers conducted a genome-wide association analysis, comparing the genotypes of 536 patients with primary biliary cirrhosis to those of 1,536 people who did not have the disease. Researchers looked at more than 300,000 single-nucleotide polymorphisms (SNPs), the most common genetic variations, among the approximately 11 million known to be present in the human genome.
"There were significant differences between the patients with primary biliary cirrhosis and the control group," says Dr. Lazaridis. As a result, researchers narrowed their focus to 16 SNPs significantly linked to primary biliary cirrhosis.
In phases two and three, researchers conducted "replication" and "fine-mapping" studies to confirm the initial results and to further detail the genetic variations most closely linked to primary biliary cirrhosis.
Researchers discovered that variants of two genes, interleukin 12A (IL12A) and interleukin 12RB2 (IL12RB2), were strongly associated with primary biliary cirrhosis. These two genes constitute a pathway of the immune system. Potential therapeutic manipulation of this pathway provides new possibilities for more effective treatments of these patients, says Dr. Lazaridis.
Researchers also confirmed that the human leukocyte antigen (HLA) region of the genome is linked to primary biliary cirrhosis, an association which had been identified in previous research. "Although both the HLA region and the IL12 pathway are equally involved with susceptibility to primary biliary cirrhosis, HLA is very complicated to dissect genetically, with multiple pathways," says Dr. Lazaridis. "It will be difficult to modulate with the intention to treat, while IL12 is a single pathway and thus more amenable to treatment."
The reliability of the newly discovered association is very strong; statistically, there's about a one in 10 trillion chance that the pathway isn't linked to primary biliary cirrhosis, Dr. Lazaridis noted.
"That strong association is remarkable, given that the researchers started by looking at 300,000 genetic markers across approximately three billion base pairs that comprise our entire genetic material," he says. "Needle in a haystack doesn't begin to convey the challenge of this search."
Dr. Lazaridis describes this finding as the "end of the beginning" in learning more about the predisposing genetic factors to primary biliary cirrhosis. The newly discovered IL12 pathway does not account for all instances of primary biliary cirrhosis. There is more work to be done on additional genetic links, and exactly how IL12A and IL12RB2 contribute to primary biliary cirrhosis remains unknown. But researchers now have, for the first time, the knowledge to begin to develop targeted treatments and better predict outcomes for some patients with primary biliary cirrhosis.
Mayo Clinic
Research identifies 3-D structure of key nuclear pore building block
The genome of complex organisms is stashed away inside each cell's nucleus, a little like a sovereign shielded from the threatening world outside.
Mayo Clinic's new imaging technology accurately identifies a broad spectrum of liver disease
A new study shows that an imaging technology developed by Mayo Clinic researchers can identify liver fibrosis with high accuracy and help eliminate the need for liver biopsies. Liver fibrosis is a common condition that can lead to incurable cirrhosis if not treated in time.
Common bacteria activating natural killer T cells may cause autoimmune liver disease
A bacteria commonly found in soil and water triggered autoimmune symptoms in mice similar to those found in an incurable liver disease called Primary Biliary Cirrhosis (PBC).
New research may lead to earlier diagnosis and treatment of primary biliary cirrhosis in families
Mayo Clinic researchers have found that first-degree relatives (i.e., parents, siblings, children) of patients with primary biliary cirrhosis (PBC) are more likely to have the biomarker of the disease in their blood.
More Primary Biliary Cirrhosis Current Events and Primary Biliary Cirrhosis News Articles
 |
The Official Patient's Sourcebook on Primary Biliary Cirrhosis by James N. Parker (Editor), Philip M. Parker (Editor) This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to primary biliary cirrhosis (also Cholangiolitic biliary cirrhosis; Hanot syndrome; Hypertrophic cirrhosis of Hanot), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some of the latest official information available to date on primary... |
 |
Primary Biliary Cirrhosis Awareness Ribbon Mouse Pad by MyHeritageWear.com The Primary Biliary Cirrhosis Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Primary Biliary Cirrhosis Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Primary Biliary Cirrhosis Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
The First Year: Cirrhosis: An Essential Guide for the Newly Diagnosed (First Year, The) by James L. Dickerson (Author), Fredric Regenstein (Foreword) More than 25 million Americans and 92 million worldwide suffer from liver disease and cirrhosis, a degenerative and potentially fatal condition in which liver cells are damaged and then replaced by scar tissue, impeding liver function. The disease is most commonly caused by excessive alcohol consumption, hepatitis, or complications from prescription drugs. Immediately after his diagnosis, James Dickerson set out to educate himself on all of his options — and found there is hope for recovery. Now, he offers The First Year: Cirrhosis, the first guide for patients and their families to understanding and managing this chronic condition. In clear, accessible language, the book walks readers step-by-step through everything they need to do each day of the first week after a cirrhosis... |
 |
Primary Biliary Cirrhosis - From Pathogenesis to Clinical Treatment by Keith D. Lindor (Editor), E. Jenny Heathcote (Editor), Raoul E. Poupon (Editor) This volume, the proceedings of a one-day symposium held in Chicago, USA, on November 6, 1997, provides an update for hepatologists, gastroenterologists, and basic scientists with an interest in primary biliary cirrhosis. New insights into the pathogenesis and the natural history of the disease are discussed, and approaches to management of the complications as well as newer therapeutic options are presented by internationally recognized authors. It is intended that this book will help foster new and better approaches for the management of patients with primary biliary cirrhosis. |
|
Novel therapy may soothe severe itching due to primary biliary cirrhosis. (Liver Support Device).: An article from: Skin & Allergy News by Bruce Jancin (Author) This digital document is an article from Skin & Allergy News, published by International Medical News Group on February 1, 2003. The length of the article is 570 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Novel therapy may soothe severe itching due to primary biliary cirrhosis. (Liver Support Device). Author: Bruce Jancin Publication: Skin & Allergy News (Magazine/Journal) Date: February 1, 2003 Publisher: International Medical News Group Volume: 34 Issue: 2 Page: 31(1) Distributed by Thomson... | |
|
Antibodies, ALT Guide Biopsy in Primary Biliary Cirrhosis. (Liver Biopsy avoidable in most patients).: An article from: Internal Medicine News by Kathryn DeMott (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on January 1, 2002. The length of the article is 461 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Antibodies, ALT Guide Biopsy in Primary Biliary Cirrhosis. (Liver Biopsy avoidable in most patients). Author: Kathryn DeMott Publication: Internal Medicine News (Magazine/Journal) Date: January 1, 2002 Publisher: International Medical News Group Volume: 35 Issue: 1 Page: 11(1) Distributed by Thomson... | |
 |
Primary Biliary Cirrhosis, An Issue of Clinics in Liver Disease (The Clinics: Internal Medicine) by E. Jenny Heathcote (Author) Primary biliary cirrhosis (PBC) is a disease characterized by inflammatory destruction of the small bile ducts within the liver. PBC eventually leads to cirrhosis of the liver. The cause of PBC is unknown, but because of the presence of autoantibodies, it is generally thought to be an autoimmune disease. Other causes, such as infectious agents, have not been completely excluded. In this issue, the guest editor has expert authors present information on important topics such as epidemiology of PBC, pathogenesis of PBC, medical therapies, and liver transplantation in PBC. |
|
Gale Encyclopedia of Medicine: Primary biliary cirrhosis by J. Ricker Polsdorfer MD (Author) The article is excerpted from Gale Encyclopedia of Medicine. Consult the second edition of this authoritative, comprehensive, in-depth medical guide for information on more than 1,700 medical topics in language accessible to adult laypersons. Presented in a single alphabetical sequence, articles range in length from one or two paragraphs for minor topics, to several pages or more for major topics. Disease/disorder articles typically cover definition; description; causes and symptoms; diagnosis; treatments; prevention; and more. Test/treatment articles typically cover definition; purposes; precautions; preparation; risks; normal and abnormal results; and much more. This second edition includes more than 200 new entries, 300 updated entries, approximately 650 color... | |
 |
Primary Biliary Cirrhosis - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References by ICON Health Publications (Author) In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.This book was created for medical professionals, students, and members of the general public who want to conduct medical research using the most advanced tools available and spending the least amount of time doing so. |
|
CLINICS IN LIVER DISEASE: Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, and Adult Cholangiopathies by LINDOR & DICKSON, eds GITLIN (Author) |
| © 2009 BrightSurf.com |